Xiao-dong Z. Zhu

Zhongshan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 113 publications

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.

Journal: Lancet (London, England)

Published: April 29, 2026

Association Between Preoperative Albumin Supplementation and Postoperative Outcomes in Hypoalbuminemia Patients After Hepatocellular Carcinoma Hepatectomy: REAL Study.

Association Between Preoperative Albumin Supplementation and Postoperative Outcomes in Hypoalbuminemia Patients After Hepatocellular Carcinoma Hepatectomy: REAL Study.

Journal: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

Published: February 23, 2026

Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.

Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.

Journal: Hepatology (Baltimore, Md.)

Published: September 04, 2025

Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.

Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.

Journal: Hepatology (Baltimore, Md.)

Published: September 04, 2025

Stable Disease without Tumor Shrink Cannot Benefit from Surgery following Immune-Based Therapy in Potentially Resectable Hepatocellular Carcinoma.

Stable Disease without Tumor Shrink Cannot Benefit from Surgery following Immune-Based Therapy in Potentially Resectable Hepatocellular Carcinoma.

Journal: Liver cancer

Published: August 14, 2025

Risk Factors for Recurrence in Patients with Hepatocellular Carcinoma After Curative Resection or Ablation.

Risk Factors for Recurrence in Patients with Hepatocellular Carcinoma After Curative Resection or Ablation.

Journal: Journal of hepatocellular carcinoma

Published: July 08, 2025

Temporal Patterns and Risk Factors for Pulmonary Embolism Associated with Antitumor Therapies in Patients with Lung Cancer.

Temporal Patterns and Risk Factors for Pulmonary Embolism Associated with Antitumor Therapies in Patients with Lung Cancer.

Journal: Annals of vascular surgery

Published: June 25, 2025

CXCL6 Reshapes Lipid Metabolism and Induces Neutrophil Extracellular Trap Formation in Cholangiocarcinoma Progression and Immunotherapy Resistance.

CXCL6 Reshapes Lipid Metabolism and Induces Neutrophil Extracellular Trap Formation in Cholangiocarcinoma Progression and Immunotherapy Resistance.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: February 17, 2025

Adjuvant Lenvatinib for High-Risk CNLC IIb/IIIa Hepatocellular Carcinoma After Curative Hepatectomy: A Prospective Exploratory Study.

Adjuvant Lenvatinib for High-Risk CNLC IIb/IIIa Hepatocellular Carcinoma After Curative Hepatectomy: A Prospective Exploratory Study.

Journal: Journal of hepatocellular carcinoma

Published: January 08, 2025

Systemic Treatment for Unresectable Hepatocellular Carcinoma: A Surgeon's Perspective.

Systemic Treatment for Unresectable Hepatocellular Carcinoma: A Surgeon's Perspective.

Journal: Journal of hepatocellular carcinoma

Published: November 11, 2024

Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy.

Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: October 25, 2024

Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in older patients with uHCC.

Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in older patients with uHCC.

Journal: Frontiers in oncology

Published: October 23, 2024

Showing 1-12 of 113

Last Updated: 09/26/2026